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Consecutive sessions of transcranial direct
current stimulation do not remediate visual
hallucinations in Lewy body dementia: a
randomised controlled trial
Greg J. Elder1,2*, Sean J. Colloby1, Michael J. Firbank1, Ian G. McKeith1 and John-Paul Taylor1
Abstract
Background: Complex visual hallucinations are common in Lewy body dementia (LBD) and can cause significant
patient and caregiver distress. Current treatments are primarily pharmacological in nature and have limited efficacy
and associated side effects. The objective of this study was to assess the effects of consecutive sessions of
transcranial direct current stimulation (tDCS) on visual hallucination frequency and severity in LBD, at short-term
and long-term follow-up stages.
Methods: The study was a randomised, double-blind, placebo-controlled trial involving 40 participants with LBD
(Mage = 75.52 years, SDage = 8.69 years) which was conducted at a single site between November 2013 and
December 2017. Participants received two consecutive 20-min sessions of active (0.048 mA/cm2) or placebo tDCS,
separated by a 30-min break, over 5 consecutive days. The anodal electrode was applied to the right parietal cortex
(P4) and the cathodal electrode was applied to the occipital cortex (Oz). The primary outcome measure was the
Neuropsychiatric Inventory (NPI) hallucinations subscale, as completed by a caregiver/informant at baseline and day
5 (short-term) follow-up, and month 1 and month 3 (long-term) follow-up. Secondary outcome measures included
visual cortical excitability, as measured using transcranial magnetic stimulation, computerised attentional and
visuoperceptual tasks, and measures of global cognition and cognitive fluctuations.
Results: Complete study data were obtained from 36 participants. There was an overall improvement in visual
hallucinations (NPI) for both groups at day 5 relative to baseline, with a medium-to-large effect size; however,
compared to placebo, active tDCS did not result in any improvements in visual hallucinations (NPI) at day 5 relative
to baseline, or at month 1 or month 3 follow-up time points. Additionally, comparisons of secondary outcome
measures showed that active tDCS did not result in any improvements on any measure (visual cortical excitability,
attentional and visuoperceptual tasks or cognitive measures) at any time point.
Conclusions: Repeated consecutive sessions of parietal anodal tDCS, and occipital cathodal tDCS, do not improve
visual hallucinations or visuoperceptual function, or alter visual cortical excitability in LBD.
Trial registration: ISRCTN, ISRCTN40214749. Registered on 25 October 2013.
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Background
Lewy body dementia (LBD) is a term which includes de-
mentia with Lewy bodies (DLB) and Parkinson’s disease
with dementia (PDD). DLB is a common cause of degen-
erative dementia in older people after Alzheimer’s de-
mentia (AD), accounting for up to 7.5% of all diagnosed
dementia cases in secondary care [1, 2]; and in Parkin-
son’s disease (PD), dementia is a common long-term
outcome, affecting up to 80% of patients [3]. Individuals
with DLB and PDD share a common underlying
alpha-synuclein neuropathology and display similar
neuropsychological symptoms, including marked atten-
tional and visuoperceptual deficits [4, 5].
Complex visual hallucinations, which are present in up
to 80% of LBD patients, are a core symptom for the
diagnosis of DLB [2, 6]. The presence of visual hallucina-
tions is associated with behavioural and neuropsychiatric
disturbances in individuals; additionally, their presence
is associated with an increased likelihood of patient
hospitalisation and nursing home admission, and they
can negatively impact caregiver distress [7–9]. Currently,
treatments for visual hallucinations in DLB and PDD are
primarily pharmacological in nature and are typically
limited to the use of cholinesterase inhibitors and anti-
psychotic agents [10]; however, these agents have been
shown to have only limited efficacy and, in the case of
antipsychotic medications, are typically associated with
significant morbidity and mortality risks. There is
therefore an urgent need for alternative methods of
treatment.
One aetiological theory of visual hallucinations, which
is known as the deafferentation hypothesis, suggests that
impaired bottom-up processing, from the eye to the pri-
mary visual cortex, results in compensatory cortical
hyper-excitability and subsequent visual hallucinations
[10, 11]. Alternatively, it has been suggested that visual
hallucinations occur due to a combination of perceptual
and attentional deficits [12–14]. Evidence in support of
this latter model comes from work demonstrating an as-
sociation between visuoperceptual and occipital–parietal
deficits in DLB [15] and from neuroimaging perfusion
and metabolism studies, which have indicated that un-
deractivity of the posterior parietal cortex is present in
DLB and PDD [16, 17]. The parietal cortex has been
shown to have a role in attentional processing [18], and
it is plausible that parietal hypoactivity contributes to
visual hallucinations due to the dorsal visual stream al-
terations apparent in individuals with DLB who hallucin-
ate [19]. Visual cortical excitability, measured using
transcranial magnetic stimulation (TMS), has been
shown to positively associate with the frequency and se-
verity of caregiver-rated visual hallucinations in DLB;
notably, participants with a greater visuoperceptual def-
icit displayed a greater level of cortical excitability and
more severe visual hallucinations [20]. Additionally, re-
cent neuropathological and magnetic resonance imaging
data demonstrate a relative loss of regional visual cor-
tical inhibition in both DLB and PDD respectively [21,
22]. Therefore, the modulation of visual cortical excit-
ability can potentially reduce the frequency and severity
of visual hallucinations.
One method by which cortical excitability can be altered
is through the use of transcranial direct current stimula-
tion (tDCS), which is an inexpensive, non-invasive brain
stimulation technique. This involves the application of a
weak electrical current (typically < 2mA) which is deliv-
ered to the brain through scalp electrodes contained
within saline or conductive gel-soaked holding bags. The
effects of tDCS modulate cortical excitability in a
polarity-dependent manner, where anodal stimulation in-
creases and cathodal stimulation reduces the subsequent
underlying membrane potential by several millivolts [23,
24]. Studies have demonstrated that tDCS can modulate
visual cortical function in a polarity-dependent manner,
where anodal stimulation can reduce and cathodal stimu-
lation can increase the TMS-related phosphene threshold
[25] and visual-evoked potential [26]; similarly, the appli-
cation of anodal tDCS to the right posterior parietal cor-
tex has been shown to improve visual search and
orienting abilities [27].
To date, no studies have examined the therapeutic use
of tDCS as a treatment for visual hallucinations in DLB
and PDD, although it has been shown to be both feasible
and tolerable in both patient groups [28, 29]. Whilst
tDCS can lead to short-term acute effects on cortical ex-
citability, as a single session of approximately 10 min
duration can result in after-effects lasting for 1 h [30],
repeated stimulation can result in longer-lasting cortical
effects persisting beyond 24 h [31]. Notably, the effects
of repeated stimulation upon relevant outcomes, includ-
ing executive function and motor skill acquisition, ap-
pear to be additive [32, 33] and it would therefore be
expected that the repeated application of tDCS would
result in an additive and sustained therapeutic effect.
The aim of the present study was to investigate
whether anodal tDCS, applied to the scalp overlying the
right parietal cortex, and cathodal tDCS, applied to the
midline occiput overlying the visual cortex, reduced the
frequency and severity of caregiver-assessed visual hallu-
cinations in DLB and PDD, both at short-term and
longer-term follow-up time points. The current study
also aimed to examine whether active tDCS reduced vis-
ual cortical excitability and improved visuoperceptual
function, as secondary outcome measures. Specifically, it
was hypothesised that active stimulation, compared to
placebo stimulation, would: 1) reduce the frequency and
severity of visual hallucinations in the short-term (at day
5) and at long-term (month 1 and month 3) follow-up
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periods, relative to baseline; 2) would improve visuoper-
ceptual function in the short-term and long-term, rela-
tive to baseline; 3) increase the transcranial magnetic
stimulation-related phosphene threshold at the
short-term follow-up stage, as an objective marker of
visual cortical excitability, relative to baseline.
Methods
Trial design
The study was a randomised double-blind, placebo-con-
trolled (allocation ratio of 1:1 active/placebo) trial con-
ducted at a single site (Campus for Ageing and Vitality,
Newcastle University, Newcastle upon Tyne, UK) be-
tween December 2013 and December 2017. Participants
completed baseline assessments (day 0), a treatment
week (day 1 to day 4), short-term follow-up (day 5) and
long-term follow-up (month 1 and month 3) within the
trial.
Participants
Participants who met diagnostic criteria for either prob-
able DLB or PDD [2, 4], as verified by two experienced cli-
nicians, and who were experiencing visual hallucinations
of a moderate to severe nature were recruited from clin-
ical services in the North East of England. Participants
were included if they: were ≥ 60 years of age; had no
changes to relevant anti-parkinsonian or psychotropic
medication, or cholinesterase inhibitors, for a period of 1
month prior to participation; had a Mini-Mental State
Examination (MMSE) [34] score ≥ 12; and had a sufficient
level of English to allow participation.
Exclusion criteria were: relevant skin allergies; a history
of excess alcohol intake; concurrent major psychiatric ill-
ness; significant physical illness or co-morbidities; other
neurological disorders; a history of moderate-to-severe
visual impairment secondary to glaucoma, cataract or
macular degeneration; or metallic or electronic implants
(e.g. pacemakers). The study was prospectively registered
(ISRCTN40214749, registered 25 October 2013). All par-
ticipants and their informants (participant carers/relatives)
provided written informed consent and the study was ap-
proved by an NHS Research Ethics Committee (Yorkshire
& the Humber—Leeds West Research Ethics Committee;
REC reference: 13/YH/0292).
Study settings
Day 0, day 2–4, month 1 and month 3 procedures were
completed in the participant’s usual residence (home or
care home environment). Day 1 and day 5 procedures
were completed in a clinical research environment. In
some situations (e.g. where participants were too frail to
travel to the clinical research environment), all study
procedures with the exception of TMS were completed
in the participant’s usual residence (Fig. 1).
Measures
Cognitive and neuropsychiatric measures
At day 0, cognitive function was measured using the
MMSE [34] and the Cambridge Cognitive Examination
(CAMCOG) [35]. The presence, and severity, of cognitive
fluctuations was assessed using the One Day Fluctuation
Scale (ODFAS) and the Clinical Assessment of Fluctuation
(CAF) scale respectively [36]. Extrapyramidal motor func-
tion was assessed using Part III of the Parkinson’s Disease
Rating Scale (UPDRS-III) [37] and the presence of depres-
sive symptoms was assessed using the 15-item Geriatric
Depression Scale (GDS-15) [38]. With the help of a carer/
informant, the severity of a range of neuropsychiatric
symptoms was assessed using the Neuropsychiatric Inven-
tory (NPI) [39]. The Trail Making Test A and B (TMT A/
B) [40] and the FAS verbal fluency test [41] were used to
assess executive function. Dementia severity was evaluated
using the Clinical Dementia Rating (CDR) scale [42] and
functional status was assessed using the Instrumental
Activities of Daily Living (IADL) scale [43]. Additionally,
the Clinical Global Impression (CGI) scale [44] was
used to assess the improvement of visual hallucina-
tions relative to baseline at day 5, month 1 and
month 3 (CGI—Improvement (CGI-I)).
Visual hallucinations were assessed using the halluci-
nations sub-scale of the NPI [39], with specific reference
to the occurrence of visual hallucinations in order to ex-
clude hallucinations in other modalities (e.g. auditory
hallucinations). For reliability purposes, patients were
asked whether any visual hallucinations occurred in the
previous month using screening questions derived from
the North East Visual Hallucinations Inventory III
(NEVHI) [45]; discrepancies were discussed with pa-
tients and informants, and were used to finalise NPI hal-
lucination scores.
Computerised attentional and visuoperceptual tasks
Three attentional (simple reaction time (SRT), choice re-
action time (CRT), digit vigilance (DV)) and two
forced-choice visuoperceptual (angle and motion per-
ception) computerised tasks were used in the current
study. These tasks have previously demonstrated that in-
dividuals with LBD display a differential performance
compared to other dementia groups and healthy individ-
uals [46, 47]. Computerised tasks were presented on a
laptop PC and performance was recorded using two cus-
tom response buttons, which participants held either in
their dominant hand or in both hands depending on the
task. Full details of these tasks are provided elsewhere
[47–49] and in Fig. 2.
Occipital transcranial magnetic stimulation
Visual cortical excitability was assessed using a modified
and shortened version of a previously reported TMS
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assessment [20] where participants were required to re-
port the presence or absence of phosphenes immediately
following the application of occipital TMS delivered to
visual cortical areas.
TMS was delivered using a hand-held single-pulse
70mm figure-of-eight coil connected to a monophasic
MagStim 2002 stimulator (MagStim, Dyfed, Wales),
within a surface latex grid. This consisted of 8 × 8
1cm-spaced points, which was centred on Oz and se-
cured to the participant’s scalp. Participants wore an eye
mask in order to minimise the potential influence of
light adaptation upon the phosphene threshold. Nine
grid intersection sites (2cm above, below, left and right
of Oz) were assessed for phosphenes in a
pseudo-random order.
The phosphene threshold was determined by increas-
ing the stimulator output from an initial baseline level of
50% to a maximum of 100%, in steps of 10%. Four
stimulation trials were given at each output level. If the
participant reported a phosphene, the stimulator output
was decreased in steps of 1% until the participant no
longer reported the presence of phosphenes in the four
subsequent consecutive trials. Sham stimulation trials
were randomly interspersed with active TMS trials in a
Fig. 1 Study procedure
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1:8 ratio, where the coil was tilted away from the head at
a 90° angle but where one winding remained in contact
with the scalp. For sham trials, the stimulator output
was set at 100–120% of the phosphene threshold, or at
100% stimulator power if the participant had not re-
ported the presence of a phosphene at that time point.
The final phosphene threshold was defined as the
threshold (% stimulator output) at which a phosphene
was last reported. Non-responders were allocated a
phosphene threshold of 101% to allow for the inclusion
of their data, in line with previous work [20].
Intervention
Participants received either active or placebo tDCS. Par-
ticipants received two consecutive 20-min tDCS ses-
sions, separated by a 30-min break, on 4 consecutive
weekdays (Monday–Thursday). Each session of stimula-
tion (1.2 mA) was delivered by HDCStim (Newronika
S.R.L., Milan, Italy), using two 25-cm2 electrodes soaked
in conductive gel (equivalent current density = 0.048
mA/cm2). The anodal electrode was placed over the
right posterior parietal cortex (P4 on the basis of the
International 10–20 measurement system [50]) and the
cathodal electrode was placed over Oz. During active
stimulation, the current was initially ramped up to a
current density of 0.048 mA/cm2, in proportional steps,
during a 7-s fade-in period. This was followed by a 7-s
fade-out period at the end of the stimulation. Imped-
ances were maintained at < 10 kΩ during stimulation.
During placebo stimulation, the current was ramped
up during an initial 7-s fade-in period, before imme-
diately stopping. Stimulation was administered by a
trained technician or research nurse, who were
blinded to the stimulation condition. Participants,
informants and the assessor were asked whether they
thought the participant had received active or placebo
stimulation on day 5.
Sample size calculation
As no studies have assessed the efficacy of tDCS upon
visual hallucinations in LBD, sample size calculations
were derived from a comparable study [51] where tDCS
was used to treat auditory hallucinations in schizophre-
nia (active n = 15, placebo n = 15; equivalent current
density = 0.057 mA/cm2). Participants in the active
stimulation group displayed a mean reduction of 31%
in the primary outcome measure (Auditory Hallucin-
ation Rating Scale), representing a clinical improve-
ment, and the placebo stimulation group displayed an
8% reduction. In the present study, it was determined
that the minimum clinically meaningful difference on
the primary outcome measure would be a 2-point
(16.7%) change in the score between the active and pla-
cebo groups at day 5, derived from NPI hallucination
frequency × severity scores (maximum score of 12).
The pooled standard deviation of 14.05% from Brunelin
et al. [51] was used to estimate a minimum effect size
of d = 1.19.
G*Power 3.1 [52] was used to calculate that 26
participants were required to obtain an effect size of
d = 1.19 (at 80% power; α = 0.05) and that 52 participants
were required to obtain an effect size of d = 0.80 (at 80%
power; α = 0.05). Therefore, a compromise sample size
of 40 was used in order to obtain an expected effect
size of d = 0.93 (80% power; α = 0.05). Allowing for a
10% participant drop-out rate during the study, this
resulted in a final target sample size of 44
participants.
Fig. 2 Attentional and visuoperceptual tasks: simple reaction time (a); choice reaction time (b); digit vigilance (c); angle perception (d); motion
perception (e)
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Randomisation sequence and blinding
Participants were randomised to receive either active or
placebo stimulation (1:1 ratio) on the basis of 44 random
codes, which were pre-generated by a member of the
study team (SJC), in two separate blocks using an online
computerised random generator (www.randomization.-
com). The codes were stored separately from the study
site in a sealed opaque envelope. The tDCS stimulator
was programmed to deliver either active or placebo
stimulation, using an external programming unit
(HDCProg; Newronika S.R.L.), by a statistician inde-
pendent of the study delivery team.
Statistical analyses
Day 0 (baseline) demographic details were compared be-
tween the active and placebo groups using
independent-samples t tests or Mann–Whitney U tests
where appropriate. Categorical data were compared
using chi-square tests. Effect sizes are provided using
Cohen’s d or partial eta squared (η2p).
Primary outcome measure
The primary outcome measure was the NPI hallucination
subscale total score, (frequency × severity), compared be-
tween day 0 and day 5, which was analysed using a 2
(treatment group) × 2 (time point) mixed analysis of vari-
ance (ANOVA). This analysis was pre-specified. Further
exploratory analyses during the follow-up phase compared
day 5, month 1 and month 3 NPI-B hallucination scores
using a 2 (treatment group) × 3 (time point) mixed
ANOVA for participants with complete carer/informant
data (n = 28). Finally, an exploratory between-group
responder analysis was performed using a Fisher exact
probability test, where responders were defined as
those participants who displayed a ≥ 2-point reduction
in NPI-B total (frequency × severity) scores, which
was considered to be clinically meaningful, between
day 0 and day 5.
Secondary outcome measures
Analyses of secondary measures were exploratory in na-
ture and only included participants with complete data.
TMS phosphene thresholds were compared between day
1 and day 5 using a 2 (treatment group) × 2 (time point)
mixed ANOVA. Relevant cognitive and neuropsychiatric
measures (CAMCOG, MMSE, CAF, ODFAS) were com-
pared between day 0 and day 5 using a 2 (treatment
group) × 2 (time point) mixed ANOVA. Further explora-
tory analyses during the follow-up phase compared these
measures between day 5, month 1 and month 3 using a
2 (treatment group) × 3 (time point) mixed ANOVA.
The association between day 0 NPI visual hallucination
scores and the day 0 TMS phosphene threshold was ex-
amined using a Pearson correlation.
CGI—Improvement scores, measured at day 5, were
compared between the active and placebo treatment groups
using an independent-samples t-test or Mann–Whitney U
test where appropriate. Further exploratory analyses com-
pared day 5, month 1 and month 3 CGI—Severity and
CGI—Improvement scores using a 2 (treatment group) × 3
(time point) mixed ANOVA. The integrity of blinding (par-
ticipant, carer and assessor) was assessed at day 5 using
separate chi-square tests. In order to examine whether
there was potentially a differential response to active tDCS,
based upon baseline hallucination severity, an additional
exploratory analysis investigated whether baseline NPI total
scores were different between participants, for both active
and placebo conditions, who displayed either an improve-
ment (reduction), no change or a worsening (increase) in
NPI scores at day 5 relative to day 0, using a Kruskal–Wal-
lis H test.
SRT, CRT and DV task outcome measures included
the percentage of correct answers, the mean reaction
time (RT) to correct answers and the coefficient of vari-
ation (COV), as a marker of intra-individual variability
(calculated on the basis of COV = (SDRT / MRT) × 100).
As reported previously, participant outliers (mean ≥
2SD) were removed from the SRT, CRT and DV reaction
time data [28]. Visuoperceptual angle and motion task
outcome measures included the percentage of correct
answers and the task difficulty, which was either
expressed as degree values (angle task: a lower degree
value indicates better task performance) or relative speed
values (cars task: a lower relative speed value indicates
better task performance). Attentional and visuopercep-
tual task performance was compared between active and
placebo stimulation conditions using a 2 (treatment
group) × 6 (measurement time point; day 0–day 5)
mixed ANOVA, where the p-value was corrected for
multiple comparisons. Further exploratory analyses dur-
ing the follow-up phase compared day 5, month 1 and
month 3 attentional and visuoperceptual scores using a
2 (treatment group) × 3 (time point) mixed ANOVA,
corrected for multiple comparisons.
Finally, the prevalence of passage and presence halluci-
nations, assessed on the basis of the NEVHI, were com-
pared qualitatively (i.e. no statistical analysis was
conducted) between baseline and day 5.
Results
Participant flow
A total of 40 participants (26 DLB, 14 PDD; Mage = 75.52
years, SDage = 8.69 years) were entered into the study. Four
participants dropped out of the study prior to the treatment
week, which resulted in a final treatment week sample
of 36 participants (23 DLB, 13 PDD; Mage = 75.16 years,
SDage = 7.96 years). The mean (± SD) levodopa equiva-
lent dose was 50.00 ± 160.43 mg for DLB participants
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and 485.50 ± 262.03 mg for PDD participants. Complete
TMS data (day 1 and day 5) were obtained for 30 par-
ticipants; follow-up data were obtained for 30 partici-
pants at month 1 and 29 participants at month 3
(Fig. 3). There were no significant between-group dif-
ferences on any baseline demographic or clinical meas-
ure (p-values > 0.05; Table 1).
Outcomes
Primary outcome measure
Comparisons of NPI hallucination scores (Fig. 4; Table
2) showed that there were no significant between-group
differences between day 0 and day 5, as indicated by the
non-significant group × time point interaction, F(1,34) =
0.06, p = 0.808, η2p = 0.002. The main effect of group was
not significant, F(1,34) = 0.04, p = 0.842, η2p = 0.00. The
main effect of measurement time point was significant,
F(1,34) = 10.14, p = 0.003, η2p = 0.23, indicating that both
groups showed a significant reduction in visual hallu-
cination severity between day 0 and day 5. Additional
analyses indicated that neither the DLB or PDD
group alone improved with active stimulation, relative
to placebo (Additional file 1).
Comparisons between day 5, month 1 and month 3
follow-up time points indicated that the group × time point
interaction was not significant, F(2,52) = 1.05, p = 0.357,
η2p = 0.04. The main effect of group and the main effect
of time point were not significant (p > 0.05). Additional
exploratory analyses indicated that 31 patients (active
n = 17, placebo n = 14) displayed a ≥ 2-point NPI total
Fig. 3 Participant flow diagram
Elder et al. Alzheimer's Research & Therapy            (2019) 11:9 Page 7 of 13
Table 1 Baseline participant demographic and assessment data (n = 36)
Active (n = 19) Placebo (n = 17) p
valueMean SD Mean SD
Age (years) 76.31 8.79 73.88 6.97 0.369
Gender (male/female) 15 (78.9%)/4 (21.1%) 12 (70.6%)/5 (29.4%) 0.563
DLB/PDD 12 (63.2%)/7 (36.8%) 11 (64.7%)/6 (35.3%) 0.923
Levodopa equivalent dose (mg) 225.63 318.79 186.73 264.87 0.695
Cognitive fluctuations, n (%) 18 (94.7%) 17 (100%) 0.337
Parkinsonism, n (%) 14 (73.7%) 14 (82.4%) 0.532
REM behaviour disorder, n (%) 11 (52.4%) 12 (63.2%) 0.491
MMSE 18.16 6.56 17.88 6.06 0.897
CAMCOG (total) 60.05 22.91 58.24 21.39 0.808
NPI hallucinations subscale 4.42 2.80 4.47 3.16 0.961
CAF 6.32 3.92 5.65 2.55 0.553
ODFAS 4.58 3.39 4.71 2.97 0.906
UPDRS-III 36.83 25.07 32.36 21.93 0.561
TMT A (% completion) 52.2% 47.8% 0.923
TMT B (% completion) 5.3% 5.9% 0.935
FAS 17.26 14.75 14.94 11.21 0.602
GDS-15 6.81 4.31 6.27 2.91 0.681
IADL 3.12 2.52 2.47 2.26 0.451
CDR (total) 1.24 0.71 1.29 0.56 0.790
SD standard deviation, DLB dementia with Lewy bodies, PDD Parkinson’s disease dementia, REM rapid eye movement, MMSE Mini-Mental State Examination,
CAMCOG Cambridge Cognitive Examination, NPI Neuropsychiatric Inventory, CAF Cognitive Assessment of Fluctuation, ODFAS One Day Fluctuation Scale, UPDRS-III
Unified Parkinson’s Disease Rating Scale, TMT Trail Making Test, GDS-15 Geriatric Depression Scale (15-item version), IADL Individual Activities of Daily Living; CDR
Clinical Dementia Rating
Fig. 4 Baseline and day 5 follow-up Neuropsychiatric Inventory (NPI) visual hallucination scores (n = 36)
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score improvement, which is considered clinically
meaningful, but that this was not significantly different
between active and placebo groups, χ2(1, N = 36), p = 0.650.
Secondary outcome measures
Relevant cognitive and neuropsychiatric measures (CAM-
COG, MMSE, CAF, ODFAS) were compared between day
0 and day 5 (Table 2). Active stimulation did not lead to
improvements on any measure at day 5 (all group × time
point interaction p-values > 0.05). Significant main effects
of time point were observed for MMSE, F(1,34) = 12.86, p
= 0.001, η2p = 0.27, CAF, F(1,34) = 22.00, p < 0.001, η
2
p =
0.39, and ODFAS scores, F(1,34) = 6.60, p = 0.015, η2p =
0.16, where decreases were observed for all measures, but
not the total CAMCOG score (p > 0.05).
The main effect of stimulation condition was not
significant for any measure (all p-values > 0.05). Active
tDCS did not affect the TMS-measured phosphene thresh-
old, as the group × time interaction was not significant,
F(1,28) = 0.00, p = 0.989, η2p = 0.00. The main effect of
group was not significant, F(1,28) = 0.651, p = 0.427, η2p =
0.02, and the main effect of time point was not significant,
F(1,28) = 4.16, p = 0.051, η2p = 0.13. The association be-
tween the day 0 TMS phosphene threshold and NPI visual
hallucination scores was not significant (r = 0.17, p = 0.166).
There were no significant differences in CGI-I scores
between the active and placebo groups at day 5, t(34) =
0.18, p = 0.856, d = 0.06. Comparisons between day 5,
month 1 and month 3 follow-up periods indicated for
CGI-I follow-up scores that the group × time point
interaction was not significant, F(2,52) = 0.09, p = 0.915,
η2p = 0.00, the main effect of group was not signifi-
cant, F(1,26) = 0.11, p = 0.749, η2p = 0.00, and the main
effect of time point was not significant, F(2,52) = 1.95,
p = 0.152, η2p = 0.07 (Table 3).
The integrity of blinding at day 5 was maintained for
participants, χ2(2, N = 36) = 0.76, p = 0.685, carers/family
members, χ2(2, N = 36) = 0.28, p = 0.869, and the asses-
sor, χ2(1, N = 36) = 3.66, p = 0.056.
Day 0 NPI scores were significantly different between
participants who showed a day 5 NPI improvement (re-
duction), no change, or worsening (H(2) = 10.19, p =
0.006); post-hoc Dunn’s pairwise tests indicated that
baseline NPI scores were lower in those patients who
worsened, relative to those who improved (p = 0.017), in-
dicating that participants with less severe hallucinations
worsened and those with more severe hallucinations im-
proved. Day 0 NPI scores were not significantly different
for participants in the placebo condition (p = 0.799).
Passage hallucinations were present in 16 patients at
baseline (44.4%; active n = 9, placebo n = 7) and 10 pa-
tients at Day 5 (27.8%; active n = 6, placebo n = 4) and
presence hallucinations were present in 14 patients at
baseline (38.9%; active n = 7, placebo n = 7) and 5 pa-
tients at Day 5 (13.9%; active n = 2, placebo n = 3); quali-
tatively, this indicated that the presence or absence of
these phenomena did not change following stimulation.
There were no significant between-group changes in
attentional (SRT, CRT, DV) or visuoperceptual (angle,
motion) function between day 0 and day 5, as there
Table 2 Baseline and day 5 comparisons: primary and relevant secondary outcome measures
Active (n = 19) Placebo (n = 17)
Day 0 Day 5 Day 0 Day 5
Mean SD Mean SD Mean SD Mean SD
NPI hallucinations subscale 4.42 2.80 2.84 1.74 4.47 3.16 3.12 3.31
CAMCOG 60.05 22.92 59.00 27.23 58.24 21.39 55.12 22.85
MMSE 18.16 6.56 17.42 6.58 17.88 6.06 15.24 6.98
CAF 6.32 3.92 2.95 3.32 5.65 2.55 2.65 2.62
ODFAS 4.58 3.39 3.58 3.04 4.71 2.97 2.71 3.48
TMS phosphene threshold (% output) 73.69 21.83 84.31 23.15 78.88 27.94 89.65 16.33
CGI-I N/A 3.42 1.26 N/A 3.35 0.93
SD standard deviation, NPI Neuropsychiatric Inventory, CAMCOG Cambridge Cognitive Examination, MMSE Mini Mental State Examination, CAF Clinical Assessment
of Fluctuation, ODFAS One Day Fluctuation Scale, TMS transcranial magnetic stimulation, N/A not applicable, CGI-I Clinical Global Impression Scale (Improvement)
Table 3 Day 5, month 1 and month 3 comparisons (n = 28)
Active (n = 15) Placebo (n = 13)
Day 5 Month 1 Month 3 Day 5 Month 1 Month 3
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
NPI hallucinations subscale 2.80 1.61 3.07 2.52 4.07 2.91 2.92 2.60 3.15 3.29 2.85 2.34
CGI-I 3.40 1.40 3.60 1.45 3.80 1.78 3.15 0.99 3.54 1.33 3.62 1.85
SD standard deviation, NPI Neuropsychiatric Inventory, CGI-I Clinical Global Impression—Improvement
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were no significant group × time interactions, main
effects of time point or group for any measure (all
corrected p-values > 0.0038; Table 4). Similarly, there were
no significant between-group changes when day 5, month
1 and month 3 follow-up data were examined (all main ef-
fects and interaction corrected p-values > 0.0038).
Safety and tolerability
All participants tolerated stimulation and, other than a
brief tingling sensation underneath the electrodes, no
adverse events were reported during stimulation. One
patient was hospitalised on day 4 (due to a fall) and two
patients died prior to the month 1 follow-up assessment.
However, all cases were judged to be unrelated to tDCS
(the causes of death were withdrawal of life-maintaining
care and pneumonia respectively).
Discussion
This randomised, placebo-controlled, double-blind trial
demonstrated that two 20-min sessions of anodal tDCS,
delivered to the right parietal cortex, and cathodal tDCS,
delivered to the occipital cortex, repeated over 4 con-
secutive days, did not reduce the frequency and severity
of visual hallucinations in LBD patients. This was ob-
served to be the case at short-term (day 5) and
longer-term (month 1 and month 3) follow-up time
points, relative to baseline. Additionally, the administra-
tion of tDCS did not reduce visual cortical excitability
(measured at day 5) or visuoperceptual or attentional
function, either at short-term or long-term follow-up
time points. Overall, these results suggest that tDCS had
no therapeutic effect on visual hallucinations, or on cog-
nitive functions which are implicated in the aetiology of
visual hallucinations [12–14], at either short-term or
long-term follow-up periods. However, to our know-
ledge, this is the first study to demonstrate that repeated
sessions of tDCS delivered consecutively over multiple
days is both feasible and tolerable in an LBD population.
There are a number of reasons which might explain
the negative findings observed in the present study.
Although the current electrode configuration was
chosen on the basis of aetiological models which posit
that visual hallucinations arise from a combination of
perceptual and attentional deficits [12–14], and from
work demonstrating that parietal hypoactivity is a fea-
ture of DLB [15–17] and that the parietal cortex is
Table 4 Attentional and visuoperceptual task comparisons (day 0 vs day 5)
Active n = 19 Placebo n = 17
Day 0 Day 5 Day 0 Day 5
Mean SD Mean SD Mean SD Mean SD
Attentional tasks
SRT: correct answers (%)a 94.51 6.87 91.76 14.34 89.05 15.49 85.48 22.29
SRT: mean RT (ms), correct answersb 542.36 213.12 501.36 182.91 760.89 535.01 593.98 185.55
SRT: coefficient of variation (%)a 51.99 30.36 52.17 31.54 80.83 41.47 74.17 51.63
CRT: correct answers (%)c 79.26 23.11 81.85 26.82 69.11 34.19 79.33 22.75
CRT: mean RT (ms), correct answersd 863.29 333.03 808.24 218.21 946.87 260.95 1059.19 576.05
CRT: coefficient of variation (%)e 56.86 35.59 44.83 29.18 46.68 27.93 56.56 40.12
DV: correct answers (%)f 65.45 24.11 63.37 24.73 59.07 24.92 60.37 21.76
DV: mean RT (ms), correct answersg 676.68 97.96 675.88 135.74 683.95 96.12 661.17 125.49
DV: coefficient of variation (%)h 29.90 12.23 29.77 14.08 32.21 14.56 41.27 18.68
Visuoperceptual tasks
Angle: correct answers (%)i 72.92 21.84 74.17 15.23 70.83 19.23 70.00 14.56
Angle: difficulty (degrees)i 41.34 31.79 39.89 30.47 48.48 34.65 47.87 30.83
Motion: correct answers (%)j 53.81 17.97 55.95 16.29 55.28 15.86 56.11 10.72
Motion: difficulty (relative speed)j 3.57 0.89 3.49 0.97 3.66 0.71 3.91 0.12
SD standard deviation, SRT simple reaction time, RT reaction time, CRT choice reaction time, DV digit vigilance
aActive n = 17, placebo n = 14 (due to incomplete data or removal of RT > 2SD)
bActive n = 15, placebo n = 12 (due to incomplete data or removal of RT > 2SD)
cActive n = 18, placebo n = 15 (due to incomplete data or removal of RT > 2SD)
dActive n = 16, placebo n = 11 (due to incomplete data or removal of RT > 2SD)
eActive n = 18, placebo n = 13 (due to incomplete data or removal of RT > 2SD)
fActive n = 16, placebo n = 15 (due to incomplete data or removal of RT > 2SD)
gActive n = 15, placebo n = 10 (due to incomplete data or removal of RT > 2SD)
hActive n = 16, placebo n = 13 (due to incomplete data or removal of RT > 2SD)
iActive n = 16, placebo n = 12 (due to incomplete data or removal of RT > 2SD)
jActive n = 14, placebo n = 12 (due to incomplete data or removal of RT > 2SD)
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involved in attentional processing [18], this tDCS config-
uration may not be optimal. Frontal areas are also be-
lieved to have a role in the aetiology of visual
hallucinations [10, 53]; therefore, the dorsolateral pre-
frontal cortex (DLPFC) may be an alternative thera-
peutic target, given the role of the DLPFC in top-down
cognition [54] and from previous work demonstrating
that the application of tDCS to the DLPFC can benefit
attention [55]. Alternatively, a combination of tDCS and
behavioural paradigms may reinforce or improve
bottom-up processing; for example, the combination of
tDCS and focusing attention on visual hallucinations.
Despite our use of repeated stimulation sessions, deliv-
ered consecutively over multiple days, which has been
shown to result in additive effects [32, 33], other stimu-
lation parameters, including the current density and
electrode type, may need to be adjusted in order to
maximise the efficacy of tDCS for visual hallucinations.
Whilst the current density used in the present study
(0.048mA/cm2) is broadly in alignment with other rele-
vant positive studies [27, 51], higher current densities
might be required in order to induce a positive effect.
Whilst previous LBD studies have indicated that a single
session of tDCS at higher densities (0.08 mA/cm2) is well
tolerated [28, 29], it is not known whether repeated
densities, at multiple time points over consecutive days,
would be equally well tolerated. The current flow of
tDCS can also be affected by structural brain changes
[56], and atrophy, particularly parietal and visual cortical
atrophy, is a feature of LBD [57]. However, a limitation
of the present study was that participants did not rou-
tinely undergo magnetic resonance imaging prior to par-
ticipation and therefore the extent of any atrophy was
not known. The modality of stimulation may also be a
factor; repetitive TMS has an established evidence base
in the treatment of a range of neuropsychiatric symp-
toms [58] and, compared to tDCS, has the advantage of
improved focality [59]. That said, potential disadvantages
of TMS in a clinical context include the time-consuming
and technical nature of delivery [60]. However, recent
developments in the delivery of tDCS, such as
high-density electrodes, which might further enhance
cortical excitability and result in longer-lasting effects
[61], or the application of computational techniques to
accurately model current flow [62], may improve the
therapeutic utility of tDCS. Given the relative ease of ap-
plication, low-cost nature and potential clinical applica-
tions of tDCS within a home environment, further work
should first examine whether an increased current dens-
ity or use of high-density electrodes can result in a
therapeutic effect in LBD.
Although active tDCS did not improve visual hallucina-
tions in LBD, both groups displayed a significant overall re-
duction in informant-rated visual hallucinations at day 5
relative to baseline, accompanied by a medium-to-large
effect size, irrespective of treatment. Similarly, informant-
rated short-term (ODFAS) and longer-term (CAF) cogni-
tive fluctuations improved. Global cognition, measured
using the MMSE, worsened between the same time points.
Therefore, participation in a demanding clinical trial with
multiple assessments might benefit some informant-based
clinical outcomes, but worsen objective performance, po-
tentially due to fatigue. This has implications for future
LBD trials because specific elements of research participa-
tion might benefit patients; this may include social contact,
changes in routine or involvement in cognitively stimulat-
ing activities. Future trials should also identify participants
who might respond to interventions prior to trial participa-
tion; this approach has been successfully used in a study
examining the efficacy of pimavanserin, a selective 5HT2A
antagonist, in PD psychosis, where non-specific psycho-
social therapies were used to screen participants with
neuropsychiatric symptoms [63]. In the present study, the
majority of participants displayed a clinically meaningful
improvement in NPI scores; however, among these pa-
tients, those with more severe hallucinations improved and
those with less severe hallucinations worsened, which may
reflect regression to the mean. Therefore, large
inter-individual variations in neuropsychiatric symptoms in
LBD appear to be normal and an awareness of this is im-
portant for future interventional trial design in this patient
group.
The main strength of the current study is in the
double-blind, placebo-controlled nature of the study,
as tDCS studies with dementia populations typically
lack a placebo group [64]. One potential limitation is
in the use and validity of informant-driven visual hal-
lucination assessment scales; whilst the NPI is widely
used for assessing symptom severity in clinical trials,
sensitive patient-led measurement tools are needed to
overcome potential issues with regards to accuracy
and reliability. This includes the reluctance of some
patients to disclose or fully describe their visual hallu-
cinations, and the fluctuations in insight exhibited by
patients with greater impairment [10], which can
markedly affect informant accuracy in judging visual
hallucination frequency and severity. Objective bio-
markers of VH severity are needed, and the pareidolia test
might be one such valid and reliable surrogate measure of
visual hallucinations [65]. Whilst a potential limitation of
the present study is in the concurrent use of medications
such as cholinesterase inhibitors, memantine and levo-
dopa [66–68], no between-group differences were ob-
served and medication withdrawal prior to study entry
was likely to have resulted in the clinical deterioration of
participants.
In conclusion, consecutive daily sessions of anodal
tDCS to the parietal cortex, and cathodal tDCS to the
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occipital cortex, do not benefit visual hallucinations or
visuoperceptual performance, or alter visual cortical ex-
citability, in LBD. However, intensive and demanding
clinical trials are feasible in an LBD population, and par-
ticipation may result in relevant short-term clinical
benefits.
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